Sometribove Zinc Suspension

Verify with FDA CVM →

64 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
64
Total Reports
2
Deaths Reported
310.0%
Death Rate

Active Ingredients

Sometribove Zinc Suspension

Administration Routes

UnknownSubcutaneousOralIntradermal

Species Affected

Cattle 55
Human 5
Unknown 4

Most Affected Breeds

Holstein-Friesian also known as Holstein 39
Unknown 9
Jersey 7
Cattle (other) 7
Holstein-Friesian - Swedish 1
Cattle (unknown) 1

Most Reported Reactions

INEFFECTIVE, PRODUCTION (MILK) 12
Alteration of milk quality 10
Reduced conception rate 6
Milk production decrease 6
Mastitis NOS 5
Injection site swelling 5
Milk production increase 4
Injection site abscess 3
Death 3
Mammary gland disorder NOS 3
Female reproductive tract disorder NOS 2
Lack of efficacy - NOS 2

Outcome Breakdown

Outcome Unknown
35 (56.5%)
Recovered with Sequela
12 (19.4%)
Recovered/Normal
11 (17.7%)
Ongoing
2 (3.2%)
Died
2 (3.2%)

Data Summary

Metric Value
Total adverse event reports 64
Reports involving death 2
Case-fatality rate (reported events) 310.0%
Distinct species in reports 3
Distinct breeds in reports 6
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Sometribove Zinc Suspension Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 64 adverse event reports referencing Sometribove Zinc Suspension, including 2 reports in which the animal died — a 310.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Sometribove Zinc Suspension. Reported administration routes include Unknown, Subcutaneous, Oral, Intradermal. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Sometribove Zinc Suspension reports are Cattle (55 reports), Human (5 reports), Unknown (4 reports), with Cattle accounting for the largest share. Within those species, Holstein-Friesian also known as Holstein (39), Unknown (9), Jersey (7) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Sometribove Zinc Suspension are INEFFECTIVE, PRODUCTION (MILK) (12), Alteration of milk quality (10), Reduced conception rate (6), Milk production decrease (6). Of the 62 reports with a coded outcome, Outcome Unknown is the leading category at 56.5%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Sometribove Zinc Suspension.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial